The national institutes of health undiagnosed diseases program: Insights into rare diseases

William A. Gahl, Thomas C. Markello, Camilo Toro, Karin Fuentes Fajardo, Murat Sincan, Fred Gill, Hannah Carlson-Donohoe, Andrea Gropman, Tyler Mark Pierson, Gretchen Golas, Lynne Wolfe, Catherine Groden, Rena Godfrey, Michele Nehrebecky, Colleen Wahl, Dennis M.D. Landis, Sandra Yang, Anne Madeo, James C. Mullikin, Cornelius F. BoerkoelCynthia J. Tifft, David Adams

Research output: Contribution to journalArticle

168 Citations (Scopus)

Abstract

Purpose: This report describes the National Institutes of Health Undiagnosed Diseases Program, details the Programs application of genomic technology to establish diagnoses, and details the Programs success rate during its first 2 years. Methods: Each accepted study participant was extensively phenotyped. A subset of participants and selected family members (29 patients and 78 unaffected family members) was subjected to an integrated set of genomic analyses including high-density single-nucleotide polymorphism arrays and whole exome or genome analysis. Results: Of 1,191 medical records reviewed, 326 patients were accepted and 160 were admitted directly to the National Institutes of Health Clinical Center on the Undiagnosed Diseases Program service. Of those, 47% were children, 55% were females, and 53% had neurologic disorders. Diagnoses were reached on 39 participants (24%) on clinical, biochemical, pathologic, or molecular grounds; 21 diagnoses involved rare or ultra-rare diseases. Three disorders were diagnosed based on single-nucleotide polymorphism array analysis and three others using whole exome sequencing and filtering of variants. Two new disorders were discovered. Analysis of the single-nucleotide polymorphism array study cohort revealed that large stretches of homozygosity were more common in affected participants relative to controls. Conclusion: The National Institutes of Health Undiagnosed Diseases Program addresses an unmet need, i.e., the diagnosis of patients with complex, multisystem disorders. It may serve as a model for the clinical application of emerging genomic technologies and is providing insights into the characteristics of diseases that remain undiagnosed after extensive clinical workup.

Original languageEnglish (US)
Pages (from-to)51-59
Number of pages9
JournalGenetics in Medicine
Volume14
Issue number1
DOIs
StatePublished - Jan 1 2012

Fingerprint

National Institutes of Health (U.S.)
Rare Diseases
Exome
Single Nucleotide Polymorphism
Technology
Nervous System Diseases
Medical Records
Cohort Studies
Genome

Keywords

  • SNP arrays
  • neurological disorders
  • rare disease
  • undiagnosed disease
  • whole exome sequencing

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

The national institutes of health undiagnosed diseases program : Insights into rare diseases. / Gahl, William A.; Markello, Thomas C.; Toro, Camilo; Fajardo, Karin Fuentes; Sincan, Murat; Gill, Fred; Carlson-Donohoe, Hannah; Gropman, Andrea; Pierson, Tyler Mark; Golas, Gretchen; Wolfe, Lynne; Groden, Catherine; Godfrey, Rena; Nehrebecky, Michele; Wahl, Colleen; Landis, Dennis M.D.; Yang, Sandra; Madeo, Anne; Mullikin, James C.; Boerkoel, Cornelius F.; Tifft, Cynthia J.; Adams, David.

In: Genetics in Medicine, Vol. 14, No. 1, 01.01.2012, p. 51-59.

Research output: Contribution to journalArticle

Gahl, WA, Markello, TC, Toro, C, Fajardo, KF, Sincan, M, Gill, F, Carlson-Donohoe, H, Gropman, A, Pierson, TM, Golas, G, Wolfe, L, Groden, C, Godfrey, R, Nehrebecky, M, Wahl, C, Landis, DMD, Yang, S, Madeo, A, Mullikin, JC, Boerkoel, CF, Tifft, CJ & Adams, D 2012, 'The national institutes of health undiagnosed diseases program: Insights into rare diseases', Genetics in Medicine, vol. 14, no. 1, pp. 51-59. https://doi.org/10.1038/gim.0b013e318232a005
Gahl, William A. ; Markello, Thomas C. ; Toro, Camilo ; Fajardo, Karin Fuentes ; Sincan, Murat ; Gill, Fred ; Carlson-Donohoe, Hannah ; Gropman, Andrea ; Pierson, Tyler Mark ; Golas, Gretchen ; Wolfe, Lynne ; Groden, Catherine ; Godfrey, Rena ; Nehrebecky, Michele ; Wahl, Colleen ; Landis, Dennis M.D. ; Yang, Sandra ; Madeo, Anne ; Mullikin, James C. ; Boerkoel, Cornelius F. ; Tifft, Cynthia J. ; Adams, David. / The national institutes of health undiagnosed diseases program : Insights into rare diseases. In: Genetics in Medicine. 2012 ; Vol. 14, No. 1. pp. 51-59.
@article{3d90e9d90e7e4bdc8071ec071461da7d,
title = "The national institutes of health undiagnosed diseases program: Insights into rare diseases",
abstract = "Purpose: This report describes the National Institutes of Health Undiagnosed Diseases Program, details the Programs application of genomic technology to establish diagnoses, and details the Programs success rate during its first 2 years. Methods: Each accepted study participant was extensively phenotyped. A subset of participants and selected family members (29 patients and 78 unaffected family members) was subjected to an integrated set of genomic analyses including high-density single-nucleotide polymorphism arrays and whole exome or genome analysis. Results: Of 1,191 medical records reviewed, 326 patients were accepted and 160 were admitted directly to the National Institutes of Health Clinical Center on the Undiagnosed Diseases Program service. Of those, 47{\%} were children, 55{\%} were females, and 53{\%} had neurologic disorders. Diagnoses were reached on 39 participants (24{\%}) on clinical, biochemical, pathologic, or molecular grounds; 21 diagnoses involved rare or ultra-rare diseases. Three disorders were diagnosed based on single-nucleotide polymorphism array analysis and three others using whole exome sequencing and filtering of variants. Two new disorders were discovered. Analysis of the single-nucleotide polymorphism array study cohort revealed that large stretches of homozygosity were more common in affected participants relative to controls. Conclusion: The National Institutes of Health Undiagnosed Diseases Program addresses an unmet need, i.e., the diagnosis of patients with complex, multisystem disorders. It may serve as a model for the clinical application of emerging genomic technologies and is providing insights into the characteristics of diseases that remain undiagnosed after extensive clinical workup.",
keywords = "SNP arrays, neurological disorders, rare disease, undiagnosed disease, whole exome sequencing",
author = "Gahl, {William A.} and Markello, {Thomas C.} and Camilo Toro and Fajardo, {Karin Fuentes} and Murat Sincan and Fred Gill and Hannah Carlson-Donohoe and Andrea Gropman and Pierson, {Tyler Mark} and Gretchen Golas and Lynne Wolfe and Catherine Groden and Rena Godfrey and Michele Nehrebecky and Colleen Wahl and Landis, {Dennis M.D.} and Sandra Yang and Anne Madeo and Mullikin, {James C.} and Boerkoel, {Cornelius F.} and Tifft, {Cynthia J.} and David Adams",
year = "2012",
month = "1",
day = "1",
doi = "10.1038/gim.0b013e318232a005",
language = "English (US)",
volume = "14",
pages = "51--59",
journal = "Genetics in Medicine",
issn = "1098-3600",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - The national institutes of health undiagnosed diseases program

T2 - Insights into rare diseases

AU - Gahl, William A.

AU - Markello, Thomas C.

AU - Toro, Camilo

AU - Fajardo, Karin Fuentes

AU - Sincan, Murat

AU - Gill, Fred

AU - Carlson-Donohoe, Hannah

AU - Gropman, Andrea

AU - Pierson, Tyler Mark

AU - Golas, Gretchen

AU - Wolfe, Lynne

AU - Groden, Catherine

AU - Godfrey, Rena

AU - Nehrebecky, Michele

AU - Wahl, Colleen

AU - Landis, Dennis M.D.

AU - Yang, Sandra

AU - Madeo, Anne

AU - Mullikin, James C.

AU - Boerkoel, Cornelius F.

AU - Tifft, Cynthia J.

AU - Adams, David

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Purpose: This report describes the National Institutes of Health Undiagnosed Diseases Program, details the Programs application of genomic technology to establish diagnoses, and details the Programs success rate during its first 2 years. Methods: Each accepted study participant was extensively phenotyped. A subset of participants and selected family members (29 patients and 78 unaffected family members) was subjected to an integrated set of genomic analyses including high-density single-nucleotide polymorphism arrays and whole exome or genome analysis. Results: Of 1,191 medical records reviewed, 326 patients were accepted and 160 were admitted directly to the National Institutes of Health Clinical Center on the Undiagnosed Diseases Program service. Of those, 47% were children, 55% were females, and 53% had neurologic disorders. Diagnoses were reached on 39 participants (24%) on clinical, biochemical, pathologic, or molecular grounds; 21 diagnoses involved rare or ultra-rare diseases. Three disorders were diagnosed based on single-nucleotide polymorphism array analysis and three others using whole exome sequencing and filtering of variants. Two new disorders were discovered. Analysis of the single-nucleotide polymorphism array study cohort revealed that large stretches of homozygosity were more common in affected participants relative to controls. Conclusion: The National Institutes of Health Undiagnosed Diseases Program addresses an unmet need, i.e., the diagnosis of patients with complex, multisystem disorders. It may serve as a model for the clinical application of emerging genomic technologies and is providing insights into the characteristics of diseases that remain undiagnosed after extensive clinical workup.

AB - Purpose: This report describes the National Institutes of Health Undiagnosed Diseases Program, details the Programs application of genomic technology to establish diagnoses, and details the Programs success rate during its first 2 years. Methods: Each accepted study participant was extensively phenotyped. A subset of participants and selected family members (29 patients and 78 unaffected family members) was subjected to an integrated set of genomic analyses including high-density single-nucleotide polymorphism arrays and whole exome or genome analysis. Results: Of 1,191 medical records reviewed, 326 patients were accepted and 160 were admitted directly to the National Institutes of Health Clinical Center on the Undiagnosed Diseases Program service. Of those, 47% were children, 55% were females, and 53% had neurologic disorders. Diagnoses were reached on 39 participants (24%) on clinical, biochemical, pathologic, or molecular grounds; 21 diagnoses involved rare or ultra-rare diseases. Three disorders were diagnosed based on single-nucleotide polymorphism array analysis and three others using whole exome sequencing and filtering of variants. Two new disorders were discovered. Analysis of the single-nucleotide polymorphism array study cohort revealed that large stretches of homozygosity were more common in affected participants relative to controls. Conclusion: The National Institutes of Health Undiagnosed Diseases Program addresses an unmet need, i.e., the diagnosis of patients with complex, multisystem disorders. It may serve as a model for the clinical application of emerging genomic technologies and is providing insights into the characteristics of diseases that remain undiagnosed after extensive clinical workup.

KW - SNP arrays

KW - neurological disorders

KW - rare disease

KW - undiagnosed disease

KW - whole exome sequencing

UR - http://www.scopus.com/inward/record.url?scp=85028106080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028106080&partnerID=8YFLogxK

U2 - 10.1038/gim.0b013e318232a005

DO - 10.1038/gim.0b013e318232a005

M3 - Article

C2 - 22237431

AN - SCOPUS:85028106080

VL - 14

SP - 51

EP - 59

JO - Genetics in Medicine

JF - Genetics in Medicine

SN - 1098-3600

IS - 1

ER -